by Sam Collins | October 7, 2013 1:26 am
Amgen (AMGN) — This biotechnology company has been a leader in the development of genetically based research and treatment for cancer, anemia, rheumatoid arthritis and a host of other major illnesses. It markets five of the world’s best-selling biotech drugs.
Since the last Trade of the Day recommendation on July 1, with the stock near $100, S&P has increased its guidance for the company. For 2013, it raised earnings per share (EPS) estimates by 6 cents to $7.30, but reduced its 2014 estimate by 46 cents to $7.75 due to acquisition charges related to the purchase of Onyx Pharmaceuticals. Its 12-month target is $128.
Technically AMGN has formed a bullish inverse head-and-shoulders with a trading target of $130. The recent pullback following a breakout in mid-September gives investors an excellent opportunity to enter a position in this extraordinary biotech stock at just 15.5 times 2013 estimated earnings.
Source URL: http://investorplace.com/2013/10/trade-of-the-day-amgen-amgn-2/
Short URL: http://invstplc.com/1fs0EO1
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.